News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
StocksToTrade Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Senti Biosciences announced a strategic transaction to divest its gene-circuit pipeline, including lead candidate SENTI-202, to a newly formed private company, NewCo, controlled by its largest investor, Celadon. In exchange, Senti shareholders will receive Contingent Value Rights (CVRs) worth up to $60 million tied …
Senti Biosciences Inc (SNTI) has a weak financial status with a current financial score of 5.90, ranking 315 out of 385 in the Biotechnology & Medical Research industry. The company's operating efficiency is low, and relevant financial data for various metrics like quality of …
This article from TradingKey reports on Senti Biosciences Inc (SNTI) and its revenue breakdown. It states that relevant data regarding the company's business segments, regional revenue, and profit contribution have not yet been disclosed by Senti Biosciences Inc. The article provides current market data …
This article provides a detailed cash flow statement for Senti Biosciences Inc (SNTI), covering quarterly and annual figures for operating, investing, and financing activities. It also includes explanations of key cash flow terms like operating cash flow, investing cash flow, financing cash flow, and …
This article provides a risk assessment for Senti Biosciences Inc (SNTI), highlighting its volatility and financial risks. The company has a beta value of 2.11, indicating higher volatility compared to the S&P 500. It also shows various performance metrics, including significant maximum drawdowns and …
Senti Biosciences Inc. (SNTI) shows stable fundamentals and high growth potential, though its valuation is only considered "fairly valued" within the Biotechnology & Medical Research industry. Despite recent weak stock market performance, the company exhibits strong technicals and a sideways trading pattern suitable for …
This article reports on an ARS SEC filing by Senti Biosciences Holdings, Inc. (SNTI) on July 21, 2026. The filing has a low impact and neutral sentiment, and was accepted by the SEC EDGAR at 05:18 PM on the same date. The article also …
Senti Biosciences (SNTI) is registering 15.97 million shares for resale by a selling securityholder, representing 51.3% of outstanding common stock and potentially causing significant dilution. This registration is linked to Senior Secured Convertible Notes issued in May 2026, from which Senti Biosciences received $9.7 …
This article from Investing.com reports on a Form 13D/A filing related to Senti Biosciences Holdings, specifically for activity on July 16. It notes a -4.94% change for SNTI. The content primarily focuses on financial market data and investment-related topics, including stock performance and market …
Celadon-affiliated entities, holding a 54.6% stake in Senti Biosciences (SNTI), have reported a merger agreement with Senti Biosciences Holdings. This merger involves the acquisition of Senti's Gene-Circuit-enabled pipeline, including SENTI-202 rights, through Parent (Celadon Partners SPV 35). As part of the deal, Midco shareholders …
Senti Biosciences Holdings (NASDAQ: SNTI) announced a strategic transaction where its Gene-Circuit-enabled pipeline, including SENTI-202, will be acquired by a new private biotechnology company controlled by its largest investor, Celadon. In return, SBH equity holders will receive a Contingent Value Right (CVR) promising up …
Search by ticker symbol or company name and select a result to open its chart.